Replies to post #2660 on Entremed (ENMD)

[reason4]

ENMD: Antitumor Activity Shown for 2ME2 and Analogs in Preclinical Lung Cancer Models [delayed]
7/6/2005 9:42:00 AM  - Knobias



Ridgeland, MS, JUL 06, 2005 (EventX/Knobias.com via COMTEX) --

EntreMed, Inc. (ENMD) announced the presentation of results in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) preclinical models for its lead compound, 2-methoxyestradiol (2ME2 or Panzem(R) NCD). EntreMed collaborators presented results from these studies during the 11th World Conference on Lung Cancer held in Barcelona, Spain, July 3-6, 2005. Shares of ENMD are trading higher in early action by 12.5%.

Results demonstrated that 2ME2 and 2ME2 analogs effectively inhibited the in vitro growth of 19 distinct NSCLC and SCLC cell lines. Moreover, when evaluated in vivo, Panzem(R) NCD demonstrated a statistically significant, dose-dependent increase in survival in an orthotopic animal model of NSCLC. 2ME2 is an orally active small molecule that attacks tumor cells through multiple mechanisms of action including inducing apoptosis, inhibiting angiogenesis, and disrupting microtubules. Analogs of 2ME2, developed by EntreMed scientists by modifying its chemical structure, have demonstrated enhanced antitumor and antiangiogenic properties and improved metabolism while retaining 2ME2's multiple mechanisms of action.GET KNOBIAS IN REAL-TIME: Delivery of this proprietary Knobias alert has been delayed by at least 10 minutes. To get all Knobias alerts in real-time daily, visit http://www.knobias.com/cmtx

ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.Knobias.com, [e-mail]://www.knobias.com/cmtx

Copyright 2004 Knobias.com, LLC, All rights reserved.